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Summary Spheroids of a small-cell lung cancer (SCLC) cell line POC were used to evaluate the uptake and
penetration of two antibodies recognising different SCLC antigens. Spheroids approximately 300-400 gm in
diameter were incubated with 1 jig ml- "25I-labelled NY.3DI 1, an antibody which reacts with the cluster I
group antigen (neural cell adhesion molecule; NCAM) and ['25I]SWAI 1, which binds to the cluster w4 antigen.
The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and
maximum uptake occurred by 24 h. The mean uptake per spheroid at 24 h was 0.97 ng for [251I]NY.3D1 I and
0.45 ng for [125I]SWA1 1. An objective measurement of antibody penetration into spheroids was developed
using a computerised image analysis of immunostained sections of spheroids. The concentration of antibody
and incubation times were varied. Both antibodies penetrated the spheroids to a depth of 50 ILm after 30 min.
This increased to about 100 txm after 4 h incubation with I or 100 fig ml-' SWAI 1. The results with I lg mlh'
NY.3D1 were similar, but in the presence of 100 jg ml-' NY.3DII penetration into the spheroid was deep
and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetra-
tion of cluster I and cluster w4 antibodies in this spheroid model and they have implications for the selection
of antibodies for targeted therapy of SCLC.
Successful therapy with antibody conjugates is most likely to
be achieved in tumours in which the burden of cells is low
and tumour foci are small. Studies in animals with human
tumour xenografts have demonstrated that the most favour-
able anti-tumour antibody uptake ratio is seen in small
tumours (Rogers et al., 1986; Pedley et al., 1987), and this
probably accounts for the good results of radioimmuno-
therapy in these animals (Cheung et al., 1986; Buchegger et
al., 1989; Smith et al., 1991). In man radiolabelled antibodies
have usually been given to treat large tumours, and although
responses occur they are rarely sustained. It is likely that the
best results of radioimmunotherapy in man will occur when
treatment is given as an adjuvant to eradicate persistent
micrometastases.
Small-cell lung cancer (SCLC) is a tumour ideally suited to
adjuvant antibody-targeted therapy as about half the patients
treated with current chemotherapy and radiation protocols
enter a complete remission. However, subclinical disease re-
mains as more than 95% of these patients eventually die of
their disease (Souhami & Law, 1990). Antibody-targeted
radiotherapy could be given to patients in complete remission
as at this time individual tumour foci may contain about
109 cells, i.e. 1 cm3 or less. The success of this approach will
depend on delivering sufficient antibody to residual tumour
deposits and on choosing a radiopharmaceutical with appro-
priate characteristics for the size of the tumour (Gaze et al.,
1992).
There are many antibodies that react with SCLC antigens
and that could be considered as suitable agents for targeted
therapy. Several of these have been grouped into clusters
defined by two international workshops on the basis of a
common pattern of reactivity (Souhami et al., 1988, 1991).
Radiolabelled antibodies against clusters 1 and w4 have been
shown to localise SCLC growing as a xenograft in 'nude
mice' (Yoneda et al., 1988; Smith et al., 1989; Wilson et al.,
1990; Boerman et al., 1991), and clinical studies to examine
their biodistribution and ability to localise in tumours are in
progress.
Studies comparing the uptake of different antibodies to
SCLC can be performed in mice with xenograft tumours, but
it is uncertain whether the results predict the behaviour of
such antibodies in man. Studies comparing the uptake of
antibodies by tumours are not easily performed in man as it
is difficult to obtain tissue. Multicellular tumour spheroids
represent an intermediate level of complexity between single
cells in vitro and solid tumours in vivo. They have some of
the characteristics of human micrometastases (Sutherland &
Durand, 1984) and they have been used as a model to
compare the microdistribution of different anti-tumour
antibodies (Sutherland et al., 1987) and to evaluate targeted
radiotherapy (Gaze et al., 1992).
We have used a human SCLC spheroid model to compare
the behaviour of two antibodies that are potential vehicles
for antibody-directed radiotherapy of SCLC. One antibody is
directed against the cluster 1 antigen, the neural cell adhesion
molecule (NCAM) (Patel et al., 1989) expressed on SCLC,
and the other is against the cluster w4 antigen (Smith et al.,
1989), which has recently been shown to be identical to a
leucocyte activation antigen CD24 (Jackson et al., 1992).
Materials and methods
Cells and spheroid culture
The POC cell line obtained from P. Twentyman (MRC,
Cambridge, UK) and the UCH10 cell line (Kardamakis et
al., 1988) were used. The SCLC cell lines POC and UCH1O
were maintained in RPMI-1640 containing 10% FCS (Gibco
Laboratories) and 2 mM glutamine at 37°C in a 5% carbon
dioxide incubator. Spheroids were initiated by inoculating
5 x I04 cells into a 75 ml tissue culture flask containing 50 ml
of medium. POC cells grew spontaneously as spheroids in
flat-bottomed tissue culture flasks. The size of spheroids was
measured using a calibrated ocular eyepiece on a phase-
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contrast microscope. Spheroids were harvested usually 7-10
days after inoculation, when their diameter was approxi-
mately 300-400 pm. They were disaggregated either
mechanically using a pipette or enzymatically using trypsin in
order to obtain single-cell suspensions for flow cytometry.
Monoclonal antibodies
The monoclonal antibody NY.3DI was raised following
immunisation of RBS/DNJ mice (Robertsonian 8:12 trans-
location) with live UCH10 cells. Spleen cells from immune
animals were fused with the Fox NY, NS-1 variant myeloma
line. NY.3DI was selected using an indirect immunofluores-
cence assay which detected antibodies that bound to a mouse
fibroblast cell line transfected with the human muscle NCAM
gene (a gift from F.S. Walsh, Guy's Hospital, London, UK).
SWAl is an IgG2a antibody that recognises the cluster w4
antigen (Smith et al., 1989). Antibodies were purified from
tissue culture supernatant by protein A-Sepharose
chromatography. Two anti-NCAMs, ERIC-1, an IgGI
(Bourne et al., 1991), and an IgG2a antibody (both supplied
by J. Kemshead, ICRF, Frenchay Hospital, Bristol, UK)
were used as positive controls. A locally produced IgGI
antibody, QS4120, an anti-human CD4 (P. Beverley, per-
sonal communication) was used as a negative control
antibody.
Antibodies were radiolabelled with 1251I by the iodogen
method with a specific activity of approximately 1 mCi mg-'.
Antibody immunoreactivity was determined using a cell-
binding assay (Trucco & de Petris, 1981). A fixed amount of
antibody (approximately 16,500 c.p.m.) was added to a range
of UCH1O cells (107 to 6.25 x 106) for 2 h at 4°C. After
washing bound counts were measured and the number of
unbound counts was plotted (y-axis) against the reciprocal
cell number. The difference between input and unbound
counts at the intercept on the y-axis gives the theoretical
immunoreactive fraction at an infinite excess of antigen.
Antibody affinity (K) and binding sites (n) were determined
as described by Trucco and de Petris (1981). Serial twofold
dilutions of radiolabelled antibody were added to 106 UCH10
cells in minimum essential medium (MEM) and 2% fetal calf
serum (FCS) and left for 2 h on ice. After washing bound
counts were measured. The results were expressed as a plot
of r against rA - X, where r is the number of antibody
molecules bound per cell and A -X is the free antibody
expressed as c.p.m.
Binding ofantibodies to POC cells
An indirect immunofluorescence assay was used to establish
binding of all three antibodies to POC cells. A single-cell
suspension was prepared and 50 p1 of a 10 ig ml- solution
of NY.3D11, ERIC 1 or SWAll in MEM with 2% FCS was
added. Antibodies were incubated with approximately
2 x 105 cells for 1 h on ice. Following washing fluorescein-
conjugated anti-mouse immunoglobulin was added for
45 min on ice. After further washing cells were analysed on a
fluorescence-activated cell sorter (FACScan, Becton Dickin-
son).
Uptake ofradiolabelled antibodies by spheroids
Radiolabelled antibody, diluted to pg ml1' in MEM con-
taining 2% FCS, was incubated with ten spheroids in 1.5 ml
Eppendorf tubes for various times at 37°C. Tubes were
agitated periodically and supernatant was removed and
spheroids were gently washed with buffer. Experiments were
performed in duplicate and the results were expressed as the
mean quantity of antibody bound per ten spheroids.
Penetration ofantibodies into spheroids
Spheroids were incubated with I ml of antibody at either I or
100 pg ml- in RPMI containing 2% FCS for 30min or 4 h.
The supernatant medium was carefully removed with a
pipette and a few drops of cryo-embedding medium, OCT
(Miles), was introduced into the tube held at an angle. A
small pipette was used to gently agitate the spheroids and lift
them from the bottom of the tube so that the embedding
medium could penetrate around them. The whole sealed tube
was immersed in liquid nitrogen. The conical-shaped block
was mounted on a metal cyrostat chuck at - 30°C and 7pim
sections were cut through the tip of the block.
Immunohistochemical localisation ofantibody
Sections were fixed in 10% buffered formalin for 5 min and
bound antibody was localised using an avidin-biotin- peroxi-
dase technique. Briefly, sections were incubated with
biotinylated horse anti-mouse immunoglobulin for 30 min,
washed in Tris-buffered saline and then incubated with
avidin-biotin-peroxidase complexes reagent (Vector
Laboratories, UK) for 50 min. Sites of antibody binding were
demonstrated following addition of substrate, diaminoben-
zidine tetrahydrochloride. Staining for the cluster 1 or w4
antigen using SWAl1 or NY.3Dll, or for the presence of
antibody following incubation, was performed on serial sec-
tions of spheroid with approximately equivalent diameters.
An image analyser that used an 8-bit greyscale program,
'Image', on a Macintosh computer was used to measure the
depth of penetration of antibodies. At least two sets of
experiments were performed for each antibody.
Results
Uptake ofcluster I and w4 antibodies in SCLC spheroids
The antibody NY.3D11 binds to human NCAM expressed
on the surface of cells. In the experiment shown in Figure 1
the antibody was incubated with D243, a mouse fibroblast
cell line that had been transfected with cDNA encoding the
140 kDa isoform of human skeletal muscle NCAM. NCAM
is expressed on the surface of these cells and the fluorescence
histogram (Figure la and b) shows binding of NY.3D11 to
D243 but not to the parent mouse fibroblast line. Both
NY.3D11 and SWAl1 bound to the two SCLC lines, POC
and UCH1O cells (Figure Ic and d).
POC spheroids with a diameter of 300-400 1m contained
about 104 cells. The proporton of dividing cells was not
determined, but visible signs of necrosis were not apparent
until the diameter exceeded 500pLm. The binding affinity of
NY.3D1I1 and SWA 11 for UCH1O cells is shown in Figure 2.
The immunoreactive fraction determined by the method of
Trucco and de Petris (1981) was usually 50-60% of the
labelled preparation. Preliminary separate experiments with
['25I]SWA 1 and [125I]NY.3D1 1 had shown that the affinity of
the two antibodies for their antigen was similar and approxi-
mately 108 M-1. In a paired experiment the affinity of the two
antibodies for UCH10 cells was 2.3 x 108M-I for NY.3D11
and 1.1 x 108M-I for SWAl . There were approximately
4.4 x I05 binding sites per cell for NY.3D1 1 and 2.3 x 106
sites for SWAl1.
The rates of uptake of the cluster 1 and w4 antibodies by
POC spheroids were similar. During the first 8 h of incuba-
tion there was a rapid increase in uptake of ['251]NY.3D11
and [1251]SWAI1 antibodies, and this was followed by a
slower accumulation thereafter. No significant increase in
uptake of antibody was seen beyond 24h (Figure 3). The
mean absolute uptake of ['25I]NY.3D11 was 0.44 ng per
spheroid at 4 h, increasing to 0.97 ng by 24 h. In contrast, the
mean absolute uptake of [1251]SWA1 1 was 0.13 ng at 4 h and
0.45 ng by 24 h. The uptake kinetics of another anti-NCAM,
['251I]ERIC-1, was similar to that of ['251I]NY.3DI 1, and the
mean absolute uptake of this antibody was 0.37 ng and
0.83 ng per spheroid at 4 and 24 h respectively. The uptake
of [12511]4120 at the same time points was 0.14 ng and
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Figure 1 Fluorescence histogram demonstrating a, The binding of NY.3D1 1 to D243 (NCAM transfectant); and b, The parent
mouse fibroblast (L cells). Binding of NY.3Dl and SWAl to UCH1O and POC cells is shown in c and d. Solid lines represent
fluorescence following incubation of FITC-labelled anti-mouse immunoglobulin only (control).
Penetration ofantibodies into SCLC spheroids
Computerised image analysis was used to provide an objec-
tive measurement of the depth of penetration of antibodies.
It showed that differences in the penetration of the two
antibodies into spheroids were not significantly different in
the presence of 1 tLg ml-' antibody but were strikingly
different in the presence of 100 sg ml- ' (Figure 4). The distri-
bution of NY.3D1 across the spheroid section was fairly
uniform, but deposition of SWA 11 was seen mainly in a rim
extending no more than 100 gm from the surface of the
spheroid. These differences are clearly seen in the photo-
micrographs shown in Figure 5. Following 30 min incubation
NY.3Dl and SWAl had penetrated to a depth of about
3-4 cell layers (50gtm) from the surface of the spheroid. The
intensity of staining of SWA 11 at 4 h is greater than
NY.3D 1, but the latter has penetrated more deeply and
diffusely into the spheroid. The antibodies appeared to be
localised around the surface of the cells. No uptake of the
control antibody, QS4120, was seen at 4 h.
Direct incubation of tissue sections with antibody showed
a homogeneous distribution of cluster 1 and cluster w4
antigens (Figure 4). Antigen was not detected in areas of
central necrosis seen in some spheroids larger than 400 .tm in
diameter. A high intensity of staining was seen at the rim of
the spheroids stained for antigen. This peak is unlikely to be
an artefact due to high concentrations of antibody in the
surrounding medium. It could have been due to tissue shrin-
kage during penetration of the spheroid or to a true increase
in the concentration of antigen at the surface of the
spheroid.
Discussion
The purpose of this study was to compare the uptake and
penetration of two distinct antibodies to SCLC antigens in
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Figure 2 Scatchard plot showing the binding of a, ['251]SWAI 1;
and b, ['25I]NY.3DIl to UCHIO cells. For SWAIl the affinity
(K) = 1.1 x 108MI and the number of binding sites per cell
(n)=2.3xI06. For NY.3Dl1, K=2.3x108M-' and
n= 4.4 x 105.
SCLC tumours. Human tumour spheroids were used as they
have some features in common with micrometastatic SCLC.
Both radiolabelled cluster 1 and cluster w4 antibodies have
been shown to have therapeutic activity in animals with
SCLC xenograft tumours (Yoneda et al., 1988; Smith et al.,
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Figure 3 Uptake of 251I-labelled antibodies to cluster 1 and w4
antigens and control antibody (I jig ml-') in POC spheroids.
Mean uptake and standard deviation are shown.
1991) and cluster 1 and w4 antigens are commonly found in
tumours of patients (Souhami et al., 1991). The patterns of
uptake of NY.3DII and SWAl1 in POC spheroids were
similar. A rapid phase of accumulation during the first 8 h
was followed by only a small increase in uptake over the next
16 h. The decrease in uptake of radiolabelled antibody after
8 h was not due to exhaustion of the supply of antibody as
only a small fraction of antibody in the incubation medium
bound to spheroids. The results are similar to those reported
in studies of human melanoma, colon and ovarian carcinoma
spheroids (Kwok et al., 1988; Langmuir et al., 1990; Bardies
et al., 1992). However, a clear difference in the absolute
amount of anti-SCLC antibody accumulating in the
spheroids was seen. Following incubation with 1 fig ml-'
antibody for 24 h each spheroid contained about 1 ng of
[125I]NY.3D1 1. This was approximately twice the amount of
['251]SWAl 1. Similar results were obtained with the anti-
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NCAM, ERIC-1, which suggests that the different behaviour
was due to interaction of the antibody with its antigen. It is
possible that the 72a subclass of SWA 11 behaved differently
from the y1 subclass of NY.3D 1. However, when we used an
IgG2a cluster 1 antibody we did not see any difference in
penetration into the spheroid compared with the IgGl cluster
I antibody (data not shown). Antibody uptake in tumour
spheroid models can be improved by greatly increasing the
concentration of the incubating antibody (Kwok et al., 1988;
Langmuir et al., 1990; Bardies et al., 1992). Studies were
performed with 1 gig ml-1 antibody, as this is a concentration
that can be realistically maintained in the blood of patients
for several hours. Accumulation of[251I]NY.3D11 at this dose
was greater than that of ['251I]SWA11, but the difference was
not such that any change in the depth of penetration of the
two antibodies was detectable by immunohistochemistry. A
major difference in the depth of penetration of the two
antibodies was seen only with 100 Lg ml-' incubating anti-
body. While it is possible to achieve high peak levels of
antibody in blood, it is not clear whether high levels can be
sustained for a sufficient time to alter the depth of penetra-
tion of an antibody.
Most previous studies with radiolabelled antibodies have
shown that much of the radioactivity resides on the surface
or outer layers of spheroids expressing membrane antigens
(Sutherland et al., 1987; Pervez et al., 1989; Langmuir et al.,
1990; Chen et al., 1991). The inability of antibodies to pene-
trate deeply into a tumour mass reduces the efficacy of
radioimmunoconjugate therapy (Bardies et al., 1992). Much
work has been devoted to studying factors that affect the
uptake and penetration of anti-tumour antibodies in
tumours, as they have an important bearing on the success of
antibody-targeted therapy. The size of the tumour (Pedley et
al., 1987), local interstitial pressures (Jain, 1988) and size of
the immunoglobulin molecule (Sutherland et al., 1987) are all
likely to be influential factors. Furthermore, antigens may
not be homogeneously distributed on the surface membrane.
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Figure 4 a and b, Image analysis of POC spheroid sections showing the presence of cluster I or w4 antigen following incubation
with NY.3D1 1 or SWAl1 (1 figml'). The relative optical density following incubation with control antibody QS4120 was between
80 and 90. c and d, A comparison of the depth of penetration of 1O.Olgml' NY.3D11l and SWAl1 after incubation for
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Figure 5 Immunohistochemical staining demonstrating the
uptake of SWAI 1 after a, 30 min incubation with POC spheroids;
and b, 4 h incubation. Uptake of NY.3DI 1 at 4 h is shown in c.
Antibody concentration was 100 gg ml-'1. Magnification x 200.
For example, Pervez et al. (1989) have shown that in
spheroid models some antigens are expressed preferentially
on the membrane of the outer surface of the spheroid.
Nuclear antigens are exposed by necrotic cells, and this
results in preferential binding of antibody at the centre of the
spheroid (Chen et al., 1991). Antibody uptake and penetra-
tion into a tumour may also depend on antibody affinity
(Weinstein et al., 1987; Schlom et al., 1992) and
physicochemical properties of antibodies (Clauss & Jamn,
1990).
In the POC spheroid model computerised image analysis
of immunohistochemically stained tissue sections suggested
that the higher uptake of cluster 1 antibody, NY.3D 1I, was
due to its deeper penetration into the spheroid. While we did
not compare the absolute uptake of NY.3DI 1 and SWAl
into spheroids at high and low concentrations, we have
shown that the depth of penetration of SWAIl cannot be
increased to more than about 100tim from the surface. These
findings suggest there is a fundamental difference in the
behaviour of these two antibodies in this spheroid model
system.
The difference in penetration of the antibodies was not
related to the distribution ofcluster 1 and w4 antigens, which
was shown by immunohistochemistry to be fairly uniform
and on the surface membrane of cells. However, SWAl1 is
internalised by cells (Derbyshire et al., 1992), and this may
retard its penetration through spheroids. There is no evidence
that the cluster 1 antibodies are internalised (R.L. Souhami,
unpublished observations). Alternatively, differences in the
depth of penetration of antibodies into spheroids could be
related to antibody affinity. It has been suggested that the
interaction of high-affinity antibodies at the surface of a
tumour prevents its penetration (Fujimori et al., 1989; van
Osdol et al., 1991). We were unable to measure reproducibly
the affinity of the antibodies on POC cells, as it was difficult
to prepare a single-cell suspension that was not heavily con-
taminated by dead cells which accumulated radiolabelled
antibody non-specifically. There was little difference in the
affinity of SWAII and NY.3D11 on UCH1O cells which
grow as a cell suspension. It is unlikely that the affinity of
these antibodies for their antigen would be significantly
different on POC cells and we therefore believe that the
differences in the penetration of these antibodies into
spheroids are unlikely to be related to their affinity for the
antigen. However, there were approximately five times as
many antigen binding sites for SWA1 1 on UCH10 compared
with NY.3D11. Cell-binding studies by FACS analysis
showed that the mean fluorescence from SWAI1 binding to
UCH10 and POC was greater than from NY.3DII (Figure
1), suggesting that there were more antigen binding sites for
SWAl1 on both cell lines. If the antigen densities on POC
and UCH10 are similar then one could envisage that a high
density of antigen might lead to a deposition of SWA 11 near
the surface of the spheroid, forming a barrier which might
prevent further penetration of antibody. The lower density of
cluster 1 antigen might permit a more diffuse penetration of
antibody through the spheroid.
Differences in the behaviour of antibodies in the tumour
environment are difficult to measure in patients, and in par-
ticular in SCLC, in which the aim of treatment is to eradicate
small-volume residual disease. The spheroid model of SCLC
has been shown to be a useful method of studying differences
in the pattern of uptake of cluster 1 and w4 antibodies. The
results may have implications for the choice of antibody and
conjugate most likely to be effective in therapy of SCLC.
However, selection of the most suitable radiopharmaceutical
will also depend upon the results of clinical studies that
examine biodistribution and tumour localisation of these two
antibodies. We have recently shown that radiolabelled
SWAI1 localises in tumours, but it also accumulates in areas
rich in granulocytes, making it unsuitable for targeted
therapy of SCLC (Ledermann et al., 1993). A study of the
biodistribution of radiolabelled NY.3DIl in patients is to
start shortly.
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